BioNTech SE (NASDAQ:BNTX) Receives Average Recommendation of “Moderate Buy” from Analysts

BioNTech SE (NASDAQ:BNTX) has been given a consensus recommendation of “Moderate Buy” by the seventeen analysts that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $142.72.

Several equities research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $150.00 target price on shares of BioNTech in a report on Monday, November 18th. TD Cowen lowered their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. Berenberg Bank initiated coverage on BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 target price on the stock. JPMorgan Chase & Co. lowered their price target on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a report on Tuesday, November 26th. Finally, Wells Fargo & Company initiated coverage on BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price objective on the stock.

BioNTech Trading Up 1.1 %

NASDAQ BNTX opened at $113.67 on Thursday. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The stock has a 50-day simple moving average of $114.42 and a 200 day simple moving average of $104.05. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $27.25 billion, a PE ratio of -54.13 and a beta of 0.18.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s revenue was up 38.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.73 EPS. Research analysts forecast that BioNTech will post -3.72 EPS for the current year.

Institutional Trading of BioNTech

Institutional investors have recently made changes to their positions in the business. Planning Capital Management Corp increased its stake in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after buying an additional 450 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares in the last quarter. GAMMA Investing LLC increased its position in shares of BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after acquiring an additional 111 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in BioNTech by 430.3% during the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after acquiring an additional 1,562 shares in the last quarter. Finally, Clear Harbor Asset Management LLC acquired a new position in BioNTech during the third quarter valued at approximately $210,000. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.